New ‘superbug’ antibiotic to treat sepsis and pneumonia enters last phase of testing

Antibiotic for deadly superbug behind hospital infections enters final trials

An experimental antibiotic zosurabalpin to fight deadly superbug has entered the final human trials. This development could mark a turning point in combating antibiotic resistance globally.

New ‘superbug’ antibiotic to treat sepsis and pneumonia enters last phase of testing

It is hoped that the drug zosurabalpin will be approved by the end of the decade

New lifesaving antibiotic to fight sepsis and pneumonia enters final human testing phase

Zosurabalpin targets drug-resistant bacteria behind sepsis and pneumonia A potential game-changer in the fight against deadly hospital infections is entering the final stage of human trials. Swiss pharmaceutical giant Roche announced it is moving forward with Phase 3 testing of its experimental antibiotic, zosurabalpin, a drug designed to combat highly drug-resistant infections that threaten millions each year. Jointly developed with Harvard Uni…

The European Medicines Agency has restricted and eliminated several indications associated with azithromycin to reduce the risk of generating antibiotic resistance. More information: Blow to superbacteria: a new antibiotic manages to stop some of the most resistant strains.

New 'superbug' antibiotic to treat sepsis and pneumonia ...